LevelJump Announces 2025 Third Quarter Results

Executive Summary

• LevelJump Healthcare Corp. reported Q3 2025 revenue of $4.85 M (up 8.7% YoY) and nine‑month revenue of $14.1 M (up 9.1% YoY).
• EBITDA for Q3 was $600,677; nine‑month EBITDA reached $1.90 M, with subsidiary Canadian Teleradiology Services posting $836 K (Q3) and $3.04 M (nine months).
• Net loss of $(26,378) in Q3 contrasted with a modest net income of $5,754 for the nine‑month period; the previously announced acquisition of two Calgary clinics was terminated.

Key Details

• Revenue – Q3 2025: $4.85 M (↑ 8.7% vs. Q3 2024).
• Revenue – Nine months ended Sep 30, 2025: $14.1 M (↑ 9.1% vs. same period 2024).
• EBITDA – Q3 2025: $600,677.
• EBITDA – Nine months ended Sep 30, 2025: $1.90 M.
• Net loss – Q3 2025: $(26,378).
• Net income – Nine months ended Sep 30, 2025: $5,754.
• Subsidiary (Canadian Teleradiology Services) EBITDA – Q3 2025: $836,000.
• Subsidiary EBITDA – Nine months ended Sep 30, 2025: $3.04 M.
• Acquisition Update: Planned purchase of two diagnostic imaging outpatient clinics in Calgary was terminated after a landlord failed to approve the transaction (referencing June 13, 2025 release).
• Management Comment: CEO Mitch Geisler highlighted Q3 growth, ongoing organic expansion, and preparation for adding mammography, fluoroscopy, and pain‑management services in Alberta.

Notable Quotes

“We are very pleased with our Q3 results and year‑over‑year growth. We continue to focus on increasing clinic revenue with additional patient scans and other organic growth opportunities including our preparations in Alberta to add mammography and increase our fluoroscopy and pain management services.” – Mitch Geisler, CEO

All forward‑looking statements are subject to the usual risk factors disclosed in the Company’s MD&A and SEDAR filings.